Several other brokerages have also recently weighed in on MTFB. Northland Securities set a $5.00 target price on MOTIF BIO PLC/S and gave the company a buy rating in a research note on Monday, July 15th. Zacks Investment Research raised MOTIF BIO PLC/S from a sell rating to a hold rating in a research note on Tuesday.
MTFB stock traded down $0.01 during trading hours on Thursday, hitting $0.59. 22,166 shares of the stock traded hands, compared to its average volume of 73,975. The firm has a 50-day moving average of $0.69. MOTIF BIO PLC/S has a one year low of $0.58 and a one year high of $11.50.
MOTIF BIO PLC/S Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Featured Story: What are the benefits of momentum investing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.